KB-GDT

Kiromic BioPharma reports a 33.33% reduction in tumor volume in one patient with metastatic NSCLC after 12 months of Deltacel treatment.

Kiromic BioPharma reports a 32% tumor volume reduction in a patient with stage 4 metastatic NSCLC treated with Deltacel in Phase 1 trial.

Kiromic BioPharma's Deltacel T-cell therapy demonstrates disease stabilization in NSCLC patients, showing potential in advanced solid tumor treatment.

Deltacel (KB-GDT-01), an allogeneic gamma delta T-cell therapy, demonstrated a 27% reduction in tumor size in a patient with stage IV metastatic NSCLC at 10 months.

Kiromic BioPharma has activated the University of Arizona Cancer Center as the fifth clinical trial site for its Deltacel-01 Phase 1 trial.